Our Principal, Ms. Yolanda Wang, was invited to join a panel discussion on the first day of BIOHK this year, which took place on Wednesday, September 13, 2023 at HKCEC, on the topic of “Ethics in the Biotech Industry.”

The panel was moderated by Ms. Monin Ung of Mung Legal and included esteemed panelists Prof. Yi Rao from Capital Medical University and Prof. Dong Dong from CUHK.

During the discussion, Yolanda shared her experiences regarding the ethical challenges she encountered in her career in IP and provided insights on the concept of ethics in the biotech industry from the perspective of a patent practitioner.



Our Past Events

Recommended Insights

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

Markush claims in China - what can be arbitrarily deleted during invalidation?

4 December 2018
Since 2010, the China Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that […]

AI is magical but NOT magic! Be specific in your AI patents!

9 January 2025
What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

6 December 2021
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]
Top crossarrow-right